
Royalty Pharma
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $674,141 | $630,576 | $621,990 | $609,291 |
Gross Profit | 405,925 | 629,405 | 621,990 | 609,291 |
EBITDA | 176,397 | 563,149 | 451,280 | 525,052 |
EBIT | 175,103 | 561,978 | 450,084 | 523,775 |
Net Income | 17,883 | 295,000 | 214,205 | 288,217 |
Net Change In Cash | 674,141 | 630,576 | 621,990 | 609,291 |
Free Cash Flow | 686,155 | 760,539 | 827,148 | 702,615 |
Cash | 812,000 | 586,395 | 619,000 | 938,944 |
Basic Shares | 556,896 | 559,611 | 559,611 | 559,611 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $2,378,193 | $2,263,576 | $2,354,554 | $2,237,215 |
Gross Profit | 2,378,193 | 2,263,576 | 2,354,554 | 2,237,215 |
EBITDA | 1,635,708 | 1,556,325 | 1,887,275 | 423,695 |
EBIT | 1,631,856 | 1,292,444 | 1,492,150 | 418,025 |
Net Income | 770,947 | 858,983 | 1,134,834 | 42,832 |
Net Change In Cash | 2,378,193 | 2,263,576 | 2,354,554 | 2,237,215 |
Cost of Revenue | 169,703 | |||
Free Cash Flow | 2,489,823 | 2,768,986 | 2,987,802 | 4,185,132 |
Cash | 618,696 | 929,026 | 477,010 | 1,710,751 |
Basic Shares | 559,611 | 594,000 | 602,900 | 564,931 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | $1.32 |
2026-03-31 | $1.30 |
2025-12-31 | $1.47 |
2025-09-30 | $1.17 |